Appoints Dan Lochner as Chief Financial Officer Appoints John Snisarenko as Chief Commercial Officer PRINCETON, N.J. – SEPTEMBER 19, 2019 – Oyster Point Pharma, Inc., today announced the appointment... read more →
PRINCETON, N.J. – July 24, 2019 – Oyster Point Pharma, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular... read more →
PRINCETON, New Jersey – April 25, 2019 – Oyster Point Pharma, Inc., a privately held clinical-stage pharmaceutical company with an initial focus on developing novel therapies for the treatment of... read more →
PRINCETON, New Jersey – March 5, 2019 – Oyster Point Pharma, Inc., a privately held clinical-stage pharmaceutical company with an initial focus on developing novel therapies for the treatment of... read more →
PRINCETON, N.J. – February 26, 2019 – Oyster Point Pharma, Inc., a privately held clinical-stage pharmaceutical company with an initial focus on developing novel therapies to treat Dry Eye Disease,... read more →
PRINCETON, New Jersey – February 21, 2019 – Oyster Point Pharma, Inc., a privately held clinical-stage pharmaceutical company with an initial focus on developing novel therapies for the treatment of... read more →
PRINCETON, New Jersey – January 24, 2019 – Oyster Point Pharma, Inc., a privately held clinical-stage pharmaceutical company with an initial focus on developing novel therapies for the treatment of... read more →
PRINCETON, New Jersey – January 3, 2019 – Oyster Point Pharma, Inc., a privately held clinical-stage pharmaceutical company with an initial focus on developing novel therapies for the treatment of... read more →
--Two Lead Clinical Candidates are Delivered as a Nasal Spray to Stimulate the Trigeminal Parasympathetic Pathway to Promote Natural Tear Film Production-- PRINCETON, New Jersey - October 24, 2018 -... read more →
PRINCETON, New Jersey – July 12, 2018 – Oyster Point Pharma, Inc., today announced results from the PEARL study, a Phase 2b clinical trial evaluating the company’s novel therapy for... read more →